HANSHOW
15.9.2022 09:01:41 CEST | Business Wire | Press release
September 2022, Hanshow, a professional digital store solution provider (SP), has officially released a whitepaper called “Hanshow Works with Intel and Microsoft to Accelerate Smart Retail Innovation”，written jointly by Hanshow, Intel, and Microsoft. It summarizes changes in the global retail industry and best practices in the retail + AI sector. By examining Hanshow’s partners in China, Japan, and Europe, the whitepaper also illustrates how smart retail technology in the AI era works for global retailers and describes the future development and application trend of AI technology in the retail industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907005647/en/
Smart store powered by Hanshow (Photo: Business Wire)
AI Technology Innovation Improves Business & Customer Experience
Digitalization is reshaping the global retail industry. Innovative technologies, including AI, computer vision, and the Internet of Things (IoT), are therefore becoming the core tools helping retailers reduce operating costs, improve efficiency, and bring unique shopping experiences to customers. More retailers are using AI technology as a key element to improve business, increase revenue, gain insights into consumer preferences, and optimize store operations.
Liangyan Li SVP, Head of Global Sales, Hanshow, said “Hanshow shall cooperate with leading international companies such as Intel and Microsoft to continuously explore the evolution of AI + retail, unlock the value of data, provide more retailers with better products and solutions, and contribute to the transformation of the global retail market.”
Hanshow Joins Intel and Microsoft to Launch AI Retail Program
Together with Intel and Microsoft, Hanshow therefore has launched AI solutions for the retail industry, focusing on smart shelf management and self-service cashier loss prevention. The use of technology, such as AI cameras and robots, enables retailers to determine the amount of displayed and out-of-stock products with an accuracy of over 95%, by collecting data through commodity identification, and stock inspection. Meanwhile, the edge devices in the scheme solve the problem of sensitive data protection, as well as collect and transmit relevant data for further processing to help businesses find trends and make decisions.
Long-Term Transformative Benefits of AI Solutions for the Retail Industry
The partnership among Hanshow, Intel, and Microsoft in the retail sector has successfully driven the application of AI in the industry. Especially in the post-pandemic period, the digital transformation of the retail industry will help retailers to provide users with a unique and personalized offline service experience to regain their interest and achieve higher business growth.
Guo Wei, General Manager of NEX and Channel DCAI Sales team, PRC Sales Organization, Intel, said " With digital technologies such as AI, virtualization, IoT, and edge computing realizing the upgrade of personalized consumer experiences and the reshaping of innovation-driven retail, the industry is experiencing a lot of changes. ”
Rashmi Misra, General Manager, Microsoft AI & Emerging Technologies, said "AI and IoT are transforming business models by helping companies move from simply making products and services, to companies that give their customers desired outcomes and impeccable experience."
Raj Raguneethan, Regional Business Lead, Retail & Consumer Goods, Microsoft Asia, said “Through the extensive application of AI, retail can become smart, providing better operational excellence, intelligent supply chain, and stronger business intelligence."
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow is used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom